Levetiracetam low-dose - AgeneBio

Drug Profile

Levetiracetam low-dose - AgeneBio

Alternative Names: AGB-101; Low-dose levetiracetam - AgeneBio

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer AgeneBio; Johns Hopkins University
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Mild cognitive impairment

Most Recent Events

  • 19 Sep 2017 AgeneBio plans the phase III HOPE4MCI trial for Mild cognitive impairment due to Alzheimer's disease in USA in the first quarter of 2018
  • 31 Mar 2017 AgeneBio's low-dose Levetiracetam is still at phase II development stage for Mild cognitive impairment in USA (PO)
  • 10 Jan 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top